Tests L-citrulline as add-on treatment in adults with obesity and late-onset asthma
Tests L-citrulline against placebo in adults with obesity and late-onset asthma.
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Durham, United StatesSee the site
- Trial code
- Registry title
- Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 1 Oct 2021
- Planned end
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- L-ctirulline
- Matching Placebo
- Record updated
- 10 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with asthma and obesity whose asthma started at age 12 or later and is not well controlled. They take L-citrulline or placebo.
- Age
- 18 to 65 years
- Sex
- All sexes can join
- Disease stage
- Doctor-diagnosed asthma that started at age 12 or later, with BMI of 30 or more, FEV1 of at least 50% of predicted, FeNO of 30 ppb or less, and poor control (ACQ of 0.50 or more, or ACT of 19 or less).
- Earlier treatment
- Regular treatment with ICS, ICS/LABA or LAMA combination medication for at least 1 month. Biologics are allowed. No smoking in the last 3 months.
- Biomarker or test result
- FeNO of 30 ppb or less.
Main reasons for not taking part
- Respiratory infection in the last 4 weeks
- Steroid burst or asthma-related ER visit in the last 4 weeks
- ICU stay or intubation for asthma in the past year, or 3 or more steroid-treated flare-ups in the past year
- Chronic renal failure or untreated sleep apnea
- Allergy to L-arginine or L-citrulline, or use of PDE5 drugs or oral mononitrates
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Adequate completion of informed consent process
- Male and female patients
- Physician diagnosis of asthma
- Able to perform reproducible spirometry according to ATS criteria
- Pre-bronchodilator FEV1 >/= 50% of predicted at Visit 0
- Confirmation of asthma
- All racial/ethnic backgrounds may participate
- BMI >/= 30
- Regular treatment with ICS or ICS/LABA or LAMA combination medication for at least 1 month; participants can be on biologics
- Smoking history </= 10 pack years and no smoking in the last 3 months
- Age of asthma onset (diagnosis) >/= 12 years
- FeNO </= 30 ppb
- ACQ >/= 0.50 or ACT </=19
Who cannot take part
- Respiratory tract infection within the 4 weeks prior to Visit 1
- Oral or systemic corticosteroid burst (for any indication) within the 4 weeks prior to Visit 0. (One-time doses, such as intra-articular injections into a shoulder or knee joint, require a 4-week washout prior to Visit 0)
- Asthma-related ER visit within the previous 4 weeks of Visit 0
- 3 or more asthma exacerbations requiring treatment with systemic corticosteroids for more than three days in the past year consistent with severe asthma
- Asthma exacerbation requiring systemic corticosteroids within the 4 weeks prior to Visit 0
- Concomitant use of PDE5 drugs or oral mononitrates
- Participant in an interventional drug study or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study
- History of ICU admission/intubation due to asthma in the past 1 year
- Chronic renal failure
- Intolerance or allergy to L-arginine or L-citrulline
- Positive urine (or serum) pregnancy test at Visit 0 or at any time during the study
- Positive urine cotinine or THC test on the day of the bronchoscopy visit
- Untreated sleep apnea
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Duke University (Asthma, Allergy and Airway Center)Durham, United StatesContact: Antoinette Santoro, MS, BSRTTaking people
About the trial
What the trial wants to find out
Patients with obese late onset (after childhood) asthma can have lower FeNO levels, yet be highly symptomatic and poorly responsive to inhaled steroids. This is a common asthma phenotype, particularly among females. This reduction of NO occurs through increased arginase activity and uncoupling of NO synthase (NOS), by accumulation of asymmetric di-methyl arginine (ADMA), which further lowers the L-arginine/ADMA ratio, preferentially promoting reactive oxygen species (ROS) formation and inflammation at the expense of NO. Indeed, in patients with obese late onset asthma, lower L-arginine/ADMA plasma ratios are associated with reduced FeNO, increased bronchial hyperreactivity, and greater asthma morbidity. In our pilot studies, the administration of L-citrulline, as an L-arginine donor, to patients with obese late onset asthma increased the L-arginine/ADMA ratio, FeNO levels, and improved asthma control and lung function. Therefore, the objectives of the protocol are to: a) determine the efficacy of L-citrulline, as an add-on treatment to improve the asthma control and lung function in obese late onset asthmatics; b) leverage the use of asthmatic and control cells to further understand obesity-related changes in epithelial airway NO metabolism, and how these changes relate to bronchoconstriction and lung function, c) determine airway epithelial changes in mitochondrial function and bioenergetics in obese late onset asthmatics and how these are modified by L-citrulline. To do this, 54 obese late onset asthmatics with suboptimal control will be blindly randomized, in a cross over study, comparing 15g/day of L-citrulline vs. placebo, in two 8-week treatment periods with a 6-week washout in between. The co-primary study outcomes are asthma control (ACQ, ACT) and FeNO, and secondary endpoints plasma L-arginine/ADMA, FEV1 and PC20 methacholine. Parallel to this study, a small study of 10 healthy obese controls will receive open label L-citrulline for 7 weeks to establish comparative reference values for the study aims. During the initial treatment phase, 50% of study participants will be randomly allocated to undergo pre and post L-citrulline treatment bronchoscopy to obtain BAL and airway epithelial cells. The research group proposing this study is highly experience in asthma clinical trials, implementation of cross over design studies, and in the use of research bronchoscopies.
The 2 groups in the trial
- L-citrullineTreatment being tested
L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
Treatment: L-ctirulline
- Matching PlaceboPlacebo, for comparison
Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes to Increase Airway L-arginine/ADMA Ratio and Improve Asthma Control
- Plain-language title
- Tests L-citrulline as add-on treatment in adults with obesity and late-onset asthmaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03885245, who can take part
- Record updated
- 10 June 2025